Result of AGM
RNS & Investor News
Presentation of research data at European Microbiome Summit
03 November 2016
OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it is presenting at the European Edition of the Microbiome Summit 2016 in London. The conference will be held at the Holiday Inn in Kensington on the 3rd and 4th November. This is the only conference in Europe dedicated specifically to the microbiome and its development.
The human microbiome has been acknowledged to have significant impact, not only in disease but more importantly in health and wellbeing. Major advances in next generation sequencing technologies have enabled scientific research in connecting an imbalanced microbiome to conditions as diverse as cancer, pulmonary, metabolic, inflammatory and mental/neurodegenerative disease.
The conference is credited for attracting leading research scientists, leading companies in the industry and well connected investment groups, and is a good opportunity to network with like-minded individuals.
The presentation, by Stephen O'Hara, will take place on Friday 4th November and is entitled "Targeted Microbiome Modulation: Next Generation Pre-, Pro-, and Syn-biotics".
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020